Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
A Phase I, Double blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'CG-745' Capsule in Healthy Male Volunteers
Hematologic Malignancy|Solid Tumor|Fibrosis
DRUG: Ivaltinostat|OTHER: Placebo
Plasma Pharmacokinetic measures (Cmax, Cmax-ss), up to 4 weeks|Plasma Pharmacokinetic measures (AUC max, AUCmax-ss), up to 4 weeks
The Number of Participants Who Experienced Serious or Non-Serious Adverse Events, Up to 4 weeks for each dosing cohort
A Phase I, Double blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Orally Administered 'CG-745' Capsule in Healthy Male Volunteers